[J01GA01, streptomycin, The risk or severity of adverse effects can be increased when Streptomycin is combined with Digitoxin.]
[M03AB01, succinylcholine, The risk or severity of Cardiac Arrhythmia can be increased when Succinylcholine is combined with Digitoxin.]
[J01EC01, sulfamethoxazole, The metabolism of Digitoxin can be decreased when combined with Sulfamethoxazole.]
[M04AB02, sulfinpyrazone, The metabolism of Digitoxin can be increased when combined with Sulfinpyrazone.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Sulfisoxazole.]
[N05AL01, sulpiride, The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Digitoxin.]
[L02BA01, tamoxifen, The serum concentration of Digitoxin can be increased when it is combined with Tamoxifen.]
[L01CB02, teniposide, The metabolism of Digitoxin can be decreased when combined with Teniposide.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Digitoxin.]
[B01AE07, dabigatran etexilate, The serum concentration of Digitoxin can be increased when it is combined with Dabigatran etexilate.]
[G03BA03, testosterone, The metabolism of Digitoxin can be increased when combined with Testosterone.]
[N07XX06, tetrabenazine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Tetrabenazine.]
[S03AA02, tetracycline, The metabolism of Digitoxin can be decreased when combined with Tetracycline.]
[N05AE05, lurasidone, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Lurasidone.]
[N04BC07, apomorphine, The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Digitoxin.]
[L04AX02, thalidomide, Digitoxin may decrease the cardiotoxic activities of Thalidomide.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Eribulin.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Thiothixene.]
[C01BB04, aprindine, Digitoxin may increase the arrhythmogenic activities of Aprindine.]
[S01ED01, timolol, Timolol may increase the arrhythmogenic activities of Digitoxin.]
[S01AA12, tobramycin, The risk or severity of adverse effects can be increased when Tobramycin is combined with Digitoxin.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Digitoxin.]
[L01XF01, tretinoin, Digitoxin may decrease the cardiotoxic activities of Tretinoin.]
[S01BA05, triamcinolone, The risk or severity of hypokalemia can be increased when Triamcinolone is combined with Digitoxin.]
[C03DB02, triamterene, Triamterene may decrease the excretion rate of Digitoxin which could result in a higher serum level.]
[C03AA06, trichlormethiazide, Trichlormethiazide may increase the hypokalemic activities of Digitoxin.]
[S01BA09, clobetasone, The risk or severity of adverse effects can be increased when Clobetasone is combined with Digitoxin.]
[S01BA10, alclometasone, The risk or severity of adverse effects can be increased when Alclometasone is combined with Digitoxin.]
[D07AC02, fluclorolone, The risk or severity of adverse effects can be increased when Fluclorolone is combined with Digitoxin.]
[R03BA07, mometasone, The risk or severity of adverse effects can be increased when Mometasone is combined with Digitoxin.]
[A03AA05, trimebutine, Digitoxin may increase the arrhythmogenic activities of Trimebutine.]
[S01ED04, metipranolol, Digitoxin may increase the arrhythmogenic activities of Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Digitoxin.]
[N03AC02, trimethadione, Trimethadione may increase the arrhythmogenic activities of Digitoxin.]
[N06AA06, trimipramine, The risk or severity of QTc prolongation can be increased when Trimipramine is combined with Digitoxin.]
[R06AX07, triprolidine, The risk or severity of QTc prolongation can be increased when Triprolidine is combined with Digitoxin.]
[J01FA08, troleandomycin, The metabolism of Digitoxin can be decreased when combined with Troleandomycin.]
[M03AA02, tubocurarine, The risk or severity of Cardiac Arrhythmia can be increased when Tubocurarine is combined with Digitoxin.]
[R03DX07, roflumilast, The metabolism of Digitoxin can be decreased when combined with Roflumilast.]
[L01EX04, vandetanib, The serum concentration of Digitoxin can be increased when it is combined with Vandetanib.]
[A10BH05, linagliptin, The serum concentration of Digitoxin can be increased when it is combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Digitoxin can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Digitoxin can be decreased when combined with Telaprevir.]
[J05AG05, rilpivirine, The metabolism of Digitoxin can be decreased when combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Ezogabine.]
[B01AF01, rivaroxaban, The serum concentration of Digitoxin can be increased when it is combined with Rivaroxaban.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Indacaterol.]
[B01AC24, ticagrelor, The serum concentration of Digitoxin can be increased when it is combined with Ticagrelor.]
[C08DA01, verapamil, Verapamil may increase the arrhythmogenic activities of Digitoxin.]
[N06AX09, viloxazine, The metabolism of Digitoxin can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Digitoxin can be increased when combined with Vinblastine.]
[L01CA02, vincristine, The serum concentration of Digitoxin can be increased when it is combined with Vincristine.]
[L01CA03, vindesine, Digitoxin may decrease the cardiotoxic activities of Vindesine.]
[A11HA03, vitamin E, The metabolism of Digitoxin can be increased when combined with Vitamin E.]
[B01AA03, warfarin, The metabolism of Digitoxin can be increased when combined with Warfarin.]
[N05AF05, zuclopenthixol, The metabolism of Digitoxin can be decreased when combined with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Digitoxin can be decreased when combined with Indinavir.]
[L01EC01, vemurafenib, The serum concentration of Digitoxin can be increased when it is combined with Vemurafenib.]
[L01FX05, brentuximab vedotin, The metabolism of Digitoxin can be decreased when combined with Brentuximab vedotin.]
[L01ED01, crizotinib, The metabolism of Digitoxin can be decreased when combined with Crizotinib.]
[R03DC01, zafirlukast, The metabolism of Digitoxin can be decreased when combined with Zafirlukast.]
[H05BX03, doxercalciferol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Doxercalciferol is combined with Digitoxin.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Digitoxin.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Ziprasidone.]
[G03AC10, drospirenone, The metabolism of Digitoxin can be decreased when combined with Drospirenone.]
[N02BA01, aspirin, The serum concentration of Digitoxin can be decreased when it is combined with Acetylsalicylic acid.]
[G04BD07, tolterodine, The risk or severity of QTc prolongation can be increased when Tolterodine is combined with Digitoxin.]
[C07AB03, atenolol, Atenolol may increase the arrhythmogenic activities of Digitoxin.]
[L03AB11, peginterferon alfa-2a, Digitoxin may decrease the cardiotoxic activities of Peginterferon alfa-2a.]
[A11CC03, alfacalcidol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Alfacalcidol is combined with Digitoxin.]
[J02AC03, voriconazole, The metabolism of Digitoxin can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of Cardiac Arrhythmia can be increased when Atracurium is combined with Digitoxin.]
[S01FA01, atropine, Atropine may increase the arrhythmogenic activities of Digitoxin.]
[L01EK01, axitinib, The serum concentration of Axitinib can be increased when it is combined with Digitoxin.]
[R07AX02, ivacaftor, The serum concentration of Digitoxin can be increased when it is combined with Ivacaftor.]
[H02AB11, prednylidene, The risk or severity of adverse effects can be increased when Prednylidene is combined with Digitoxin.]
[L01BC05, gemcitabine, The serum concentration of Digitoxin can be increased when it is combined with Gemcitabine.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Digitoxin.]
[L01FD02, pertuzumab, Digitoxin may decrease the cardiotoxic activities of Pertuzumab.]
[G04BD12, mirabegron, The serum concentration of Digitoxin can be increased when it is combined with Mirabegron.]
[L01XG02, carfilzomib, The serum concentration of Digitoxin can be increased when it is combined with Carfilzomib.]
[V03AX03, cobicistat, The metabolism of Digitoxin can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Digitoxin can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The serum concentration of Digitoxin can be decreased when it is combined with Enzalutamide.]
[L01EA04, bosutinib, The metabolism of Digitoxin can be decreased when combined with Bosutinib.]
[H02AA01, aldosterone, The risk or severity of adverse effects can be increased when Aldosterone is combined with Digitoxin.]
[L01EX05, regorafenib, The serum concentration of Digitoxin can be increased when it is combined with Regorafenib.]
[N05CA04, barbital, The metabolism of Digitoxin can be increased when combined with Barbital.]
[C01AA01, acetyldigitoxin, Acetyldigitoxin may increase the arrhythmogenic activities of Digitoxin.]
[J05AE04, nelfinavir, The metabolism of Digitoxin can be decreased when combined with Nelfinavir.]
[L01AA09, bendamustine, The serum concentration of Bendamustine can be increased when it is combined with Digitoxin.]
[S01GA07, brimonidine, Brimonidine may increase the bradycardic activities of Digitoxin.]
[C08CA13, lercanidipine, Lercanidipine may increase the arrhythmogenic activities of Digitoxin.]
[N03AX22, perampanel, The metabolism of Digitoxin can be increased when combined with Perampanel.]
[H01CB05, pasireotide, The metabolism of Digitoxin can be decreased when combined with Pasireotide.]
[G04BE03, sildenafil, The serum concentration of Digitoxin can be increased when it is combined with Sildenafil.]
[L01EA05, ponatinib, The serum concentration of Digitoxin can be increased when it is combined with Ponatinib.]
[B01AF02, apixaban, The serum concentration of Digitoxin can be increased when it is combined with Apixaban.]
[C10AX12, lomitapide, The serum concentration of Digitoxin can be increased when it is combined with Lomitapide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Bedaquiline.]
[C04AX11, bencyclane, Digitoxin may increase the arrhythmogenic activities of Bencyclane.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Digitoxin can be increased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, Bendroflumethiazide may increase the hypokalemic activities of Digitoxin.]
[L04AX06, pomalidomide, The serum concentration of Pomalidomide can be increased when it is combined with Digitoxin.]
[A10BK02, canagliflozin, The serum concentration of Digitoxin can be increased when it is combined with Canagliflozin.]
[J01MA15, gemifloxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Moxifloxacin.]
[A06AX06, tegaserod, The serum concentration of Digitoxin can be increased when it is combined with Tegaserod.]
[C10AC04, colesevelam, Colesevelam can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[L04AA18, everolimus, The serum concentration of Digitoxin can be increased when it is combined with Everolimus.]
[N04AC01, benztropine, The risk or severity of QTc prolongation can be increased when Benzatropine is combined with Digitoxin.]
[L01EC02, dabrafenib, The serum concentration of Digitoxin can be decreased when it is combined with Dabrafenib.]
[H05AA03, parathyroid hormone, The risk or severity of adverse effects can be increased when Parathyroid hormone is combined with Digitoxin.]
[L01EB03, afatinib, The serum concentration of Digitoxin can be increased when it is combined with Afatinib.]
[J05AJ03, dolutegravir, The serum concentration of Digitoxin can be increased when it is combined with Dolutegravir.]
[C08EA02, bepridil, Bepridil may increase the arrhythmogenic activities of Digitoxin.]
[C02KX05, riociguat, The serum concentration of Digitoxin can be increased when it is combined with Riociguat.]
[N03AF04, eslicarbazepine, The metabolism of Digitoxin can be increased when combined with Eslicarbazepine.]
[J05AP05, simeprevir, The serum concentration of Digitoxin can be increased when it is combined with Simeprevir.]
[J05AP08, sofosbuvir, The serum concentration of Digitoxin can be increased when it is combined with Sofosbuvir.]
[C01CA27, droxidopa, The risk or severity of Cardiac Arrhythmia can be increased when Droxidopa is combined with Digitoxin.]
[C07AB04, acebutolol, Acebutolol may increase the arrhythmogenic activities of Digitoxin.]
[N05CH03, tasimelteon, The metabolism of Digitoxin can be decreased when combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Digitoxin can be increased when combined with Metreleptin.]
[L04AA32, apremilast, The metabolism of Digitoxin can be increased when combined with Apremilast.]
[L02BG02, formestane, The metabolism of Digitoxin can be increased when combined with Formestane.]
[S03BA03, betamethasone, The risk or severity of adverse effects can be increased when Betamethasone is combined with Digitoxin.]
[S01ED02, betaxolol, Betaxolol may increase the arrhythmogenic activities of Digitoxin.]
[L04AC11, siltuximab, The metabolism of Digitoxin can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The metabolism of Digitoxin can be decreased when combined with Ceritinib.]
[B01AC26, vorapaxar, The serum concentration of Digitoxin can be increased when it is combined with Vorapaxar.]
[A03BA03, hyoscyamine, Hyoscyamine may increase the arrhythmogenic activities of Digitoxin.]
[L01XH04, belinostat, The serum concentration of Digitoxin can be increased when it is combined with Belinostat.]
[L01EM01, idelalisib, The metabolism of Digitoxin can be decreased when combined with Idelalisib.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Olodaterol.]
[V03AE01, polystyrene sulfonate, The risk or severity of Cardiac Arrhythmia can be increased when Tolevamer is combined with Digitoxin.]
[N05CM19, suvorexant, The serum concentration of Digitoxin can be increased when it is combined with Suvorexant.]
[A16AX10, eliglustat, The serum concentration of Digitoxin can be increased when it is combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Digitoxin can be increased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, The risk or severity of adverse effects can be increased when Dihydrostreptomycin is combined with Digitoxin.]
[L01EX09, nintedanib, The metabolism of Digitoxin can be decreased when combined with Nintedanib.]
[S03AA06, gentamicin, The risk or severity of adverse effects can be increased when Gentamicin is combined with Digitoxin.]
[J05AP09, dasabuvir, The serum concentration of Digitoxin can be increased when it is combined with Dasabuvir.]
[L01XK01, olaparib, The metabolism of Digitoxin can be decreased when combined with Olaparib.]
[B01AF03, edoxaban, The serum concentration of Digitoxin can be increased when it is combined with Edoxaban.]
[N06AX11, mirtazapine, The metabolism of Digitoxin can be decreased when combined with Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Digitoxin can be increased when combined with Secukinumab.]
[L01EF01, palbociclib, The serum concentration of Digitoxin can be increased when it is combined with Palbociclib.]
[L01EX08, lenvatinib, The serum concentration of Digitoxin can be increased when it is combined with Lenvatinib.]
[L01XH03, panobinostat, The serum concentration of Panobinostat can be increased when it is combined with Digitoxin.]
[J05AP07, daclatasvir, The serum concentration of Digitoxin can be increased when it is combined with Daclatasvir.]
[N02BE01, acetaminophen, The metabolism of Digitoxin can be increased when combined with Acetaminophen.]
[L01DC01, bleomycin, Digitoxin may decrease the cardiotoxic activities of Bleomycin.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Ivabradine.]
[J05AP06, asunaprevir, The serum concentration of Digitoxin can be increased when it is combined with Asunaprevir.]
[A04AD14, rolapitant, The serum concentration of Digitoxin can be increased when it is combined with Rolapitant.]
[G02CX02, flibanserin, The serum concentration of Digitoxin can be increased when it is combined with Flibanserin.]
[S01EC01, acetazolamide, The metabolism of Digitoxin can be decreased when combined with Acetazolamide.]
[J02AC05, isavuconazole, The serum concentration of Digitoxin can be increased when it is combined with Isavuconazole.]
[L01EB04, osimertinib, The metabolism of Digitoxin can be decreased when combined with Osimertinib.]
[J05AF13, tenofovir alafenamide, The metabolism of Digitoxin can be decreased when combined with Tenofovir alafenamide.]
[L01EE02, cobimetinib, The metabolism of Digitoxin can be decreased when combined with Cobimetinib.]
[B01AC27, selexipag, The serum concentration of Digitoxin can be increased when it is combined with Selexipag.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Digitoxin.]
[M04AB05, lesinurad, The metabolism of Digitoxin can be increased when combined with Lesinurad.]
[J05AP10, elbasvir, The serum concentration of Digitoxin can be increased when it is combined with Elbasvir.]
[J05AP11, grazoprevir, The serum concentration of Digitoxin can be increased when it is combined with Grazoprevir.]
[N05CA05, aprobarbital, The metabolism of Digitoxin can be increased when combined with Aprobarbital.]
[N02BA02, aloxiprin, The serum concentration of Digitoxin can be decreased when it is combined with Aloxiprin.]
[L01XX52, venetoclax, The serum concentration of Digitoxin can be increased when it is combined with Venetoclax.]
[D07AC11, amcinonide, The risk or severity of adverse effects can be increased when Amcinonide is combined with Digitoxin.]
[R06AB01, brompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Digitoxin.]
[C08CA01, amlodipine, Amlodipine may increase the arrhythmogenic activities of Digitoxin.]
[N05AX17, pimavanserin, The metabolism of Digitoxin can be decreased when combined with Pimavanserin.]
[C03CA02, bumetanide, The risk or severity of adverse effects can be increased when Bumetanide is combined with Digitoxin.]
[C07AA19, bupranolol, Digitoxin may increase the arrhythmogenic activities of Bupranolol.]
[N07BC01, buprenorphine, The metabolism of Digitoxin can be decreased when combined with Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Buserelin.]
[L01AB01, busulfan, Digitoxin may decrease the cardiotoxic activities of Busulfan.]
[L01XX27, arsenic trioxide, The serum concentration of Digitoxin can be increased when it is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Artemether.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Digitoxin.]
[L01XK03, rucaparib, The metabolism of Digitoxin can be decreased when combined with Rucaparib.]
[S01AA26, azithromycin, The metabolism of Digitoxin can be decreased when combined with Azithromycin.]
[L01EF02, ribociclib, The metabolism of Digitoxin can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The serum concentration of Digitoxin can be decreased when it is combined with Balsalazide.]
[N07XX16, deutetrabenazine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The risk or severity of QTc prolongation can be increased when Pregabalin is combined with Digitoxin.]
[H05BX05, calcifediol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Calcifediol is combined with Digitoxin.]
[D05AX03, calcitriol, The metabolism of Digitoxin can be increased when combined with Calcitriol.]
[A12AA04, calcium carbonate, Calcium carbonate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
[G04BA03, calcium chloride, Calcium chloride may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
[J05AE09, tipranavir, The metabolism of Digitoxin can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, Calcium gluconate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
[H03BA03, benzylthiouracil, The serum concentration of Digitoxin can be increased when it is combined with Benzylthiouracil.]
[L04AB02, infliximab, The metabolism of Digitoxin can be increased when combined with Infliximab.]
[A12AA01, calcium phosphate, Calcium Phosphate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
[L01EX10, midostaurin, The metabolism of Digitoxin can be decreased when combined with Midostaurin.]
[L04AC14, sarilumab, The metabolism of Digitoxin can be increased when combined with Sarilumab.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Delafloxacin.]
[B01AF04, betrixaban, The serum concentration of Digitoxin can be increased when it is combined with Betrixaban.]
[D01AC10, bifonazole, The metabolism of Digitoxin can be decreased when combined with Bifonazole.]
[P03AC02, bioallethrin, Digitoxin may increase the arrhythmogenic activities of Bioallethrin.]
[L01BC06, capecitabine, Digitoxin may decrease the cardiotoxic activities of Capecitabine.]
[L01XX59, enasidenib, The serum concentration of Digitoxin can be increased when it is combined with Enasidenib.]
[L01EH02, neratinib, The serum concentration of Digitoxin can be increased when it is combined with Neratinib.]
[L01FB01, inotuzumab ozogamicin, The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Digitoxin.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Vorinostat.]
[L01EM02, copanlisib, The serum concentration of Copanlisib can be increased when it is combined with Digitoxin.]
[L01EF03, abemaciclib, The serum concentration of Abemaciclib can be increased when it is combined with Digitoxin.]
[C07AB07, bisoprolol, The therapeutic efficacy of Digitoxin can be increased when used in combination with Bisoprolol.]
[J05AG03, efavirenz, The metabolism of Digitoxin can be decreased when combined with Efavirenz.]
[C07AA17, bopindolol, Bopindolol may increase the bradycardic activities of Digitoxin.]
[C03DA03, canrenone, Canrenone may decrease the excretion rate of Digitoxin which could result in a higher serum level.]
[R03BA02, budesonide, The risk or severity of adverse effects can be increased when Budesonide is combined with Digitoxin.]
[L01EL02, acalabrutinib, The metabolism of Digitoxin can be decreased when combined with Acalabrutinib.]
[J05AX18, letermovir, The metabolism of Digitoxin can be decreased when combined with Letermovir.]
[N06AA15, butriptyline, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Digitoxin may increase the arrhythmogenic activities of Acetyldigoxin.]
[N01BX04, capsaicin, The metabolism of Digitoxin can be decreased when combined with Capsaicin.]
[A10BK04, ertugliflozin, The serum concentration of Digitoxin can be increased when it is combined with Ertugliflozin.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Acrivastine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Macimorelin.]
[L02BB05, apalutamide, The serum concentration of Digitoxin can be decreased when it is combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Digitoxin can be increased when combined with Carbamazepine.]
[A06AC08, calcium polycarbophil, Calcium polycarbophil may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
[H03BB01, carbimazole, The serum concentration of Digitoxin can be increased when it is combined with Carbimazole.]
[R06AA08, carbinoxamine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Carbinoxamine.]
[C07AG02, carvedilol, Carvedilol may increase the arrhythmogenic activities of Digitoxin.]
[B02BX09, fostamatinib, The metabolism of Digitoxin can be decreased when combined with Fostamatinib.]
[N03AX24, cannabidiol, The metabolism of Digitoxin can be decreased when combined with Cannabidiol.]
[B02BX08, avatrombopag, The serum concentration of Digitoxin can be increased when it is combined with Avatrombopag.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Encorafenib.]
[L01EE03, binimetinib, The serum concentration of Binimetinib can be increased when it is combined with Digitoxin.]
[J01GB14, plazomicin, The risk or severity of adverse effects can be increased when Plazomicin is combined with Digitoxin.]
[C07AB08, celiprolol, Digitoxin may increase the arrhythmogenic activities of Celiprolol.]
[H01CC03, elagolix, The serum concentration of Digitoxin can be increased when it is combined with Elagolix.]
[L01XX62, ivosidenib, The metabolism of Digitoxin can be increased when combined with Ivosidenib.]
[P01BA07, tafenoquine, The serum concentration of Digitoxin can be increased when it is combined with Tafenoquine.]
[N03AX17, stiripentol, The metabolism of Digitoxin can be decreased when combined with Stiripentol.]
[B02BX07, lusutrombopag, The serum concentration of Digitoxin can be increased when it is combined with Lusutrombopag.]
[J05AX24, tecovirimat, The metabolism of Digitoxin can be increased when combined with Tecovirimat.]
[L01EM04, duvelisib, The metabolism of Digitoxin can be decreased when combined with Duvelisib.]
[L01EB07, dacomitinib, The serum concentration of Digitoxin can be increased when it is combined with Dacomitinib.]
[J01AA14, sarecycline, The serum concentration of Digitoxin can be increased when it is combined with Sarecycline.]
[J01AA15, omadacycline, The serum concentration of Digitoxin can be increased when it is combined with Omadacycline.]
[S01GX12, cetirizine, The risk or severity of QTc prolongation can be increased when Cetirizine is combined with Digitoxin.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Inotersen.]
[L01XK04, talazoparib, The serum concentration of Talazoparib can be increased when it is combined with Digitoxin.]
[R03BB08, revefenacin, The serum concentration of Digitoxin can be increased when it is combined with Revefenacin.]
[L01ED05, lorlatinib, The serum concentration of Digitoxin can be decreased when it is combined with Lorlatinib.]
[L04AA39, emapalumab, The metabolism of Digitoxin can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Digitoxin may decrease the cardiotoxic activities of Carmustine.]
[L01EX12, larotrectinib, The serum concentration of Digitoxin can be increased when it is combined with Larotrectinib.]
[L01EX13, gilteritinib, The metabolism of Digitoxin can be decreased when combined with Gilteritinib.]
[L01XJ03, glasdegib, The serum concentration of Digitoxin can be increased when it is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Amifampridine.]
[C01BG07, cifenline, Digitoxin may increase the arrhythmogenic activities of Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Digitoxin.]
[S01ED05, carteolol, Digitoxin may increase the arrhythmogenic activities of Carteolol.]
[P02BX04, triclabendazole, The metabolism of Digitoxin can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The metabolism of Digitoxin can be increased when combined with Esketamine.]
[L04AA42, siponimod, The metabolism of Digitoxin can be decreased when combined with Siponimod.]
[J01FA09, clarithromycin, The metabolism of Digitoxin can be decreased when combined with Clarithromycin.]
[L01EN01, erdafitinib, The serum concentration of Digitoxin can be increased when it is combined with Erdafitinib.]
[N05BA09, clobazam, The metabolism of Digitoxin can be increased when combined with Clobazam.]
[D07AB21, clocortolone, The risk or severity of adverse effects can be increased when Clocortolone is combined with Digitoxin.]
[H02AB14, cloprednol, The risk or severity of adverse effects can be increased when Cloprednol is combined with Digitoxin.]
[V03AE07, calcium acetate, Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
[L04AB01, etanercept, The metabolism of Digitoxin can be increased when combined with Etanercept.]
[V03AE02, sevelamer, Sevelamer can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[H02AB17, cortivazol, The risk or severity of adverse effects can be increased when Cortivazol is combined with Digitoxin.]
[L01EM03, alpelisib, The metabolism of Digitoxin can be increased when combined with Alpelisib.]
[L02BB06, darolutamide, The serum concentration of Digitoxin can be increased when it is combined with Darolutamide.]
[C03BX03, cicletanine, Digitoxin may increase the arrhythmogenic activities of Cicletanine.]
[L01EJ02, fedratinib, The serum concentration of Digitoxin can be increased when it is combined with Fedratinib.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Entrectinib.]
[N07XX11, pitolisant, The serum concentration of Digitoxin can be decreased when it is combined with Pitolisant.]
[J04AK08, pretomanid, The metabolism of Digitoxin can be decreased when combined with Pretomanid.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Digitoxin.]
[N04CX01, istradefylline, The serum concentration of Digitoxin can be increased when it is combined with Istradefylline.]
[C03AA09, cyclothiazide, Cyclothiazide may increase the hypokalemic activities of Digitoxin.]
[J01XX09, daptomycin, The serum concentration of Digitoxin can be increased when it is combined with Daptomycin.]
[J01DB01, cephalexin, The metabolism of Digitoxin can be decreased when combined with Cephalexin.]
[J01DB09, cephradine, The metabolism of Digitoxin can be increased when combined with Cefradine.]
[H02AB13, deflazacort, The risk or severity of adverse effects can be increased when Deflazacort is combined with Digitoxin.]
[L01FD01, trastuzumab, Digitoxin may decrease the cardiotoxic activities of Trastuzumab.]
[L01FD03, ado-trastuzumab emtansine, The serum concentration of Trastuzumab emtansine can be increased when it is combined with Digitoxin.]
[N02CC08, lasmiditan, The serum concentration of Digitoxin can be increased when it is combined with Lasmiditan.]
[B06AX03, voxelotor, The serum concentration of Digitoxin can be increased when it is combined with Voxelotor.]
[N03AX25, cenobamate, The serum concentration of Digitoxin can be decreased when it is combined with Cenobamate.]
[N02CD04, ubrogepant, The serum concentration of Digitoxin can be increased when it is combined with Ubrogepant.]
[L01FX13, enfortumab vedotin, The serum concentration of Digitoxin can be increased when it is combined with Enfortumab vedotin.]
[R06AB06, dexbrompheniramine, The risk or severity of QTc prolongation can be increased when Dexbrompheniramine is combined with Digitoxin.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dexpanthenol is combined with Digitoxin.]
[N05CM21, lemborexant, The serum concentration of Digitoxin can be increased when it is combined with Lemborexant.]
[L01XX72, tazemetostat, The metabolism of Digitoxin can be decreased when combined with Tazemetostat.]
[N02CD06, rimegepant, The serum concentration of Digitoxin can be increased when it is combined with Rimegepant.]
[J05AB16, remdesivir, The metabolism of Digitoxin can be decreased when combined with Remdesivir.]
[S01AE06, gatifloxacin, The risk or severity of QTc prolongation can be increased when Gatifloxacin is combined with Digitoxin.]
[H02CA02, osilodrostat, The metabolism of Digitoxin can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Digitoxin can be decreased when combined with Amprenavir.]
[L01EE04, selumetinib, The serum concentration of Digitoxin can be increased when it is combined with Selumetinib.]
[D07AC19, difluprednate, The risk or severity of adverse effects can be increased when Difluprednate is combined with Digitoxin.]
[M01AH02, rofecoxib, The metabolism of Digitoxin can be increased when combined with Rofecoxib.]
[L01XF03, bexarotene, The metabolism of Digitoxin can be increased when combined with Bexarotene.]
[C08CA16, clevidipine, Digitoxin may increase the arrhythmogenic activities of Clevidipine.]
[C01BD07, dronedarone, The serum concentration of Digitoxin can be increased when it is combined with Dronedarone.]
[J01FA13, dirithromycin, The metabolism of Digitoxin can be decreased when combined with Dirithromycin.]
[S03AA08, chloramphenicol, The metabolism of Digitoxin can be decreased when combined with Chloramphenicol.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Chlorcyclizine.]
[L01EH03, tucatinib, Tucatinib may decrease the excretion rate of Digitoxin which could result in a higher serum level.]
[L01EX17, capmatinib, The serum concentration of Digitoxin can be increased when it is combined with Capmatinib.]
[D07XB03, fluprednidene, The risk or severity of adverse effects can be increased when Fluprednidene is combined with Digitoxin.]
[L01EX19, ripretinib, The serum concentration of Digitoxin can be increased when it is combined with Ripretinib.]
[S01BA14, loteprednol, The risk or severity of adverse effects can be increased when Loteprednol is combined with Digitoxin.]
[C08CA17, levamlodipine, The serum concentration of Digitoxin can be increased when it is combined with Levamlodipine.]
[R06AX22, ebastine, The metabolism of Digitoxin can be decreased when combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Fostemsavir.]
[L01FX15, belantamab mafodotin, The serum concentration of Digitoxin can be increased when it is combined with Belantamab mafodotin.]
[L04AC19, satralizumab, The serum concentration of Digitoxin can be decreased when it is combined with Satralizumab.]
[P01BA01, chloroquine, The serum concentration of Digitoxin can be increased when it is combined with Chloroquine.]
[L01EX23, pralsetinib, The serum concentration of Digitoxin can be increased when it is combined with Pralsetinib.]
[C03AA04, chlorothiazide, Chlorothiazide may increase the hypokalemic activities of Digitoxin.]
[R06AB04, chlorpheniramine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Digitoxin can be increased when combined with Chlorpromazine.]
[N05AF03, chlorprothixene, The risk or severity of QTc prolongation can be increased when Chlorprothixene is combined with Digitoxin.]
[C03BA04, chlorthalidone, The risk or severity of adverse effects can be increased when Chlorthalidone is combined with Digitoxin.]
[A11CC05, cholecalciferol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Cholecalciferol is combined with Digitoxin.]
[C10AC01, cholestyramine resin, Cholestyramine can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[N02BA03, choline salicylate, The serum concentration of Digitoxin can be decreased when it is combined with Choline salicylate.]
[N06BX18, vinpocetine, Digitoxin may increase the arrhythmogenic activities of Vinpocetine.]
[B06AC06, berotralstat, The serum concentration of Digitoxin can be increased when it is combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Digitoxin can be decreased when combined with Lonafarnib.]
[M09AA01, hydroquinine, Digitoxin may increase the arrhythmogenic activities of Hydroquinine.]
[L01BB05, fludarabine, Digitoxin may decrease the cardiotoxic activities of Fludarabine.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Relugolix.]
[L04AD03, voclosporin, The serum concentration of Digitoxin can be increased when it is combined with Voclosporin.]
[P03AX07, abametapir, The serum concentration of Digitoxin can be increased when it is combined with Abametapir.]
[L01EX21, tepotinib, The serum concentration of Digitoxin can be increased when it is combined with Tepotinib.]
[L01EX25, umbralisib, The serum concentration of Digitoxin can be increased when it is combined with Umbralisib.]
[V03AF12, trilaciclib, The serum concentration of Digitoxin can be increased when it is combined with Trilaciclib.]
[N03AX10, felbamate, The metabolism of Digitoxin can be increased when combined with Felbamate.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Flumequine.]
[R03BA03, flunisolide, The risk or severity of adverse effects can be increased when Flunisolide is combined with Digitoxin.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Digitoxin.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Digitoxin.]
[S01LA08, bevacizumab, Digitoxin may decrease the cardiotoxic activities of Bevacizumab.]
[L01EK03, tivozanib, The serum concentration of Digitoxin can be increased when it is combined with Tivozanib.]
[L01FX22, loncastuximab tesirine, The serum concentration of Digitoxin can be increased when it is combined with Loncastuximab tesirine.]
[A02BA01, cimetidine, The metabolism of Digitoxin can be decreased when combined with Cimetidine.]
[N07CA02, cinnarizine, Cinnarizine may increase the arrhythmogenic activities of Digitoxin.]
[J01MB06, cinoxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Cinoxacin.]
[L01XX73, sotorasib, The serum concentration of Digitoxin can be decreased when it is combined with Sotorasib.]
[L01EN03, infigratinib, The metabolism of Digitoxin can be decreased when combined with Infigratinib.]
[S03AA07, ciprofloxacin, The metabolism of Digitoxin can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Digitoxin may decrease the cardiotoxic activities of Cisplatin.]
[N06AB04, citalopram, The metabolism of Digitoxin can be decreased when combined with Citalopram.]
[L04AA48, belumosudil, The serum concentration of Digitoxin can be increased when it is combined with Belumosudil.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Digitoxin is combined with Fexinidazole.]
[L01XX74, belzutifan, The serum concentration of Digitoxin can be decreased when it is combined with Belzutifan.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Mobocertinib.]
[V09GA01, technetium Tc 99m sestamibi, The serum concentration of Digitoxin can be increased when it is combined with Technetium Tc-99m sestamibi.]
[L04AA59, avacopan, The metabolism of Digitoxin can be decreased when combined with Avacopan.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Clemastine.]
[A12AA02, calcium glubionate, Calcium glubionate anhydrous may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
[J01FF01, clindamycin, The serum concentration of Digitoxin can be increased when it is combined with Clindamycin.]
[N06AX25, St. John's wort extract, The serum concentration of Digitoxin can be decreased when it is combined with St. John's Wort.]
[L01EA06, asciminib, The serum concentration of Digitoxin can be increased when it is combined with Asciminib.]
[J05AX10, maribavir, The serum concentration of Digitoxin can be increased when it is combined with Maribavir.]
[D07AD01, clobetasol, The risk or severity of adverse effects can be increased when Clobetasol is combined with Digitoxin.]
[D11AH08, abrocitinib, The serum concentration of Digitoxin can be increased when it is combined with Abrocitinib.]
[J04BA01, clofazimine, The serum concentration of Digitoxin can be increased when it is combined with Clofazimine.]
[C10AB01, clofibrate, The metabolism of Digitoxin can be increased when combined with Clofibrate.]
[B06AX04, mitapivat, The metabolism of Digitoxin can be increased when combined with Mitapivat.]
[L01EJ03, pacritinib, The serum concentration of Digitoxin can be increased when it is combined with Pacritinib.]
[G03GB02, clomiphene, The serum concentration of Digitoxin can be increased when it is combined with Clomifene.]
[N06AA04, clomipramine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Clomipramine.]
[S01EA04, clonidine, Clonidine may increase the atrioventricular blocking (AV block) activities of Digitoxin.]
[C01EB24, mavacamten, The serum concentration of Digitoxin can be decreased when it is combined with Mavacamten.]
[A04AA01, ondansetron, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Ondansetron.]
[A04AA02, granisetron, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Granisetron.]
[J05AX31, lenacapavir, The metabolism of Digitoxin can be decreased when combined with Lenacapavir.]
[N05AH02, clozapine, The metabolism of Digitoxin can be increased when combined with Clozapine.]
[L01EN04, futibatinib, The serum concentration of Digitoxin can be increased when it is combined with Futibatinib.]
[A10BK06, sotagliflozin, The serum concentration of Digitoxin can be increased when it is combined with Sotagliflozin.]
[J01GB12, arbekacin, The risk or severity of adverse effects can be increased when Arbekacin is combined with Digitoxin.]
[D07AC12, halometasone, The risk or severity of adverse effects can be increased when Halometasone is combined with Digitoxin.]
[H01AC08, somatrogon, The metabolism of Digitoxin can be increased when combined with Somatrogon.]
[S02DA02, cocaine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Cocaine.]
[L04AC21, bimekizumab, The metabolism of Digitoxin can be increased when combined with Bimekizumab.]
[M04AC01, colchicine, The serum concentration of Digitoxin can be increased when it is combined with Colchicine.]
[C10AC02, colestipol, Colestipol can cause a decrease in the absorption of Digitoxin resulting in a reduced serum concentration and potentially a decrease in efficacy.]
[J01XB01, colistin, The risk or severity of adverse effects can be increased when Colistin is combined with Digitoxin.]
[C01BA13, hydroquinidine, Digitoxin may increase the arrhythmogenic activities of Hydroquinidine.]
[N01AB07, desflurane, The risk or severity of QTc prolongation can be increased when Desflurane is combined with Digitoxin.]
[A04AA03, tropisetron, Digitoxin may increase the arrhythmogenic activities of Tropisetron.]
[J01FA15, telithromycin, The metabolism of Digitoxin can be decreased when combined with Telithromycin.]
[R03BA08, ciclesonide, The risk or severity of adverse effects can be increased when Ciclesonide is combined with Digitoxin.]
[R06AX27, desloratadine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Desloratadine.]
[J02AC02, itraconazole, The serum concentration of Digitoxin can be increased when it is combined with Itraconazole.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Emedastine.]
[N05BA10, ketazolam, The metabolism of Digitoxin can be decreased when combined with Ketazolam.]
[L01EA01, imatinib, The serum concentration of Digitoxin can be increased when it is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Digitoxin can be decreased when combined with Posaconazole.]
[C08CA09, lacidipine, Digitoxin may increase the arrhythmogenic activities of Lacidipine.]
[N03AX09, lamotrigine, Lamotrigine may increase the arrhythmogenic activities of Digitoxin.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Digitoxin.]
[S01BA03, cortisone, The risk or severity of adverse effects can be increased when Cortisone is combined with Digitoxin.]
[N07BC04, lofexidine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Lofexidine.]
[S01AE04, lomefloxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Lomefloxacin.]
[C08CA11, manidipine, Digitoxin may increase the arrhythmogenic activities of Manidipine.]
[S01BA08, medrysone, The risk or severity of adverse effects can be increased when Medrysone is combined with Digitoxin.]
[C07AA14, mepindolol, Mepindolol may increase the bradycardic activities of Digitoxin.]
[H02AB15, meprednisone, The risk or severity of adverse effects can be increased when Meprednisone is combined with Digitoxin.]
[R06AD07, mequitazine, The metabolism of Digitoxin can be decreased when combined with Mequitazine.]
[C01EB10, adenosine, Adenosine may increase the arrhythmogenic activities of Digitoxin.]
[C04AX01, cyclandelate, Digitoxin may increase the arrhythmogenic activities of Cyclandelate.]
[R06AE03, cyclizine, The risk or severity of QTc prolongation can be increased when Cyclizine is combined with Digitoxin.]
[C03DA04, eplerenone, Eplerenone may decrease the excretion rate of Digitoxin which could result in a higher serum level.]
[N05AD03, metylperon, Digitoxin may increase the arrhythmogenic activities of Melperone.]
[C03AA07, cyclopenthiazide, Cyclopenthiazide may increase the hypokalemic activities of Digitoxin.]
[J01FA03, midecamycin, The metabolism of Digitoxin can be decreased when combined with Midecamycin.]
[J05AF07, tenofovir disoproxil, The serum concentration of Digitoxin can be increased when it is combined with Tenofovir disoproxil.]
[L01AA01, cyclophosphamide, The metabolism of Digitoxin can be increased when combined with Cyclophosphamide.]
[S01XA18, cyclosporine, The serum concentration of Digitoxin can be increased when it is combined with Cyclosporine.]
[N06BA07, modafinil, The metabolism of Digitoxin can be increased when combined with Modafinil.]
[R06AX02, cyproheptadine, The risk or severity of QTc prolongation can be increased when Cyproheptadine is combined with Digitoxin.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Digitoxin.]
[C10AA07, rosuvastatin, The metabolism of Digitoxin can be decreased when combined with Rosuvastatin.]
[C03XA02, conivaptan, The metabolism of Digitoxin can be decreased when combined with Conivaptan.]
[G04BE09, vardenafil, The serum concentration of Digitoxin can be increased when it is combined with Vardenafil.]
[M01AH05, etoricoxib, The metabolism of Digitoxin can be decreased when combined with Etoricoxib.]
[L01DA01, dactinomycin, The serum concentration of Digitoxin can be increased when it is combined with Dactinomycin.]
[G03XA01, danazol, The metabolism of Digitoxin can be decreased when combined with Danazol.]
[L01DB02, daunorubicin, The metabolism of Digitoxin can be decreased when combined with Daunorubicin.]
[C07AB12, nebivolol, Digitoxin may increase the arrhythmogenic activities of Nebivolol.]
[N06AX06, nefazodone, The metabolism of Digitoxin can be decreased when combined with Nefazodone.]
[C01DX16, nicorandil, Digitoxin may increase the arrhythmogenic activities of Nicorandil.]
[C01CA23, theodrenaline, The risk or severity of Cardiac Arrhythmia can be increased when Theodrenaline is combined with Digitoxin.]
[M03AC11, cisatracurium, The risk or severity of Cardiac Arrhythmia can be increased when Cisatracurium is combined with Digitoxin.]
[N06AB10, escitalopram, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Escitalopram.]
[G04BD08, solifenacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Solifenacin.]
[A07EC03, olsalazine, The serum concentration of Digitoxin can be decreased when it is combined with Olsalazine.]
[N06AA01, desipramine, The metabolism of Digitoxin can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Deslanoside may increase the arrhythmogenic activities of Digitoxin.]
[S01BA11, desonide, The risk or severity of adverse effects can be increased when Desonide is combined with Digitoxin.]
[D07XC02, desoximetasone, The risk or severity of adverse effects can be increased when Desoximetasone is combined with Digitoxin.]
[H02AA03, desoxycorticosterone, The risk or severity of adverse effects can be increased when Desoxycortone is combined with Digitoxin.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Oxaliplatin.]
[N03AF02, oxcarbazepine, The metabolism of Digitoxin can be increased when combined with Oxcarbazepine.]
[S03BA01, dexamethasone, The risk or severity of adverse effects can be increased when Dexamethasone is combined with Digitoxin.]
[G04BD04, oxybutynin, The metabolism of Digitoxin can be decreased when combined with Oxybutynin.]
[L04AB04, adalimumab, The metabolism of Digitoxin can be increased when combined with Adalimumab.]
[J01CF01, dicloxacillin, The metabolism of Digitoxin can be increased when combined with Dicloxacillin.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Digitoxin.]
[A03AX04, pinaverium, Digitoxin may increase the arrhythmogenic activities of Pinaverium.]
[L01DC04, ixabepilone, The serum concentration of Digitoxin can be increased when it is combined with Ixabepilone.]
[L01EB02, erlotinib, The metabolism of Digitoxin can be decreased when combined with Erlotinib.]
[C03CA03, piretanide, The risk or severity of adverse effects can be increased when Piretanide is combined with Digitoxin.]
[L02AA01, diethylstilbestrol, The metabolism of Digitoxin can be decreased when combined with Diethylstilbestrol.]
[C08CA03, isradipine, Isradipine may increase the arrhythmogenic activities of Digitoxin.]
[D07XC04, diflucortolone, The risk or severity of adverse effects can be increased when Difluocortolone is combined with Digitoxin.]
[N02BA11, diflunisal, The serum concentration of Digitoxin can be decreased when it is combined with Diflunisal.]
[S01AA13, fusidic acid, The metabolism of Digitoxin can be decreased when combined with Fusidic acid.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Pipemidic acid.]
[S02BA08, fluocinolone acetonide, The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Digitoxin.]
[C01AA05, digoxin, Digoxin may increase the arrhythmogenic activities of Digitoxin.]
[C04AE04, dihydroergocristine, The metabolism of Digitoxin can be decreased when combined with Dihydroergocristine.]
[N02CA01, dihydroergotamine, The metabolism of Digitoxin can be decreased when combined with Dihydroergotamine.]
[A11CC02, dihydrotachysterol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Dihydrotachysterol is combined with Digitoxin.]
[J05AE08, atazanavir, The metabolism of Digitoxin can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Digitoxin.]
[H03BC01, potassium perchlorate, The serum concentration of Digitoxin can be increased when it is combined with Potassium perchlorate.]
[D07AC18, prednicarbate, The risk or severity of adverse effects can be increased when Prednicarbate is combined with Digitoxin.]
[C08DB01, diltiazem, Diltiazem may increase the arrhythmogenic activities of Digitoxin.]
[R06AA11, dimenhydrinate, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Dimenhydrinate.]
[M02AX03, dimethyl sulfoxide, The metabolism of Digitoxin can be decreased when combined with Dimethyl sulfoxide.]
[C05CA03, diosmin, The serum concentration of Digitoxin can be increased when it is combined with Diosmin.]
[R06AA02, diphenhydramine, The risk or severity of QTc prolongation can be increased when Diphenhydramine is combined with Digitoxin.]
[A03FA02, cisapride, The metabolism of Digitoxin can be decreased when combined with Cisapride.]
[S01XA23, sirolimus, The serum concentration of Digitoxin can be increased when it is combined with Sirolimus.]
[C01BA03, disopyramide, Disopyramide may increase the arrhythmogenic activities of Digitoxin.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Digitoxin.]
[S02AA12, rifamycin SV, The serum concentration of Digitoxin can be increased when it is combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Digitoxin can be increased when combined with Rifapentine.]
[N05AX08, risperidone, The risk or severity of QTc prolongation can be increased when Risperidone is combined with Digitoxin.]
[R06AE09, levocetirizine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Levocetirizine.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Digitoxin.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Digitoxin.]
[A04AD12, aprepitant, The metabolism of Digitoxin can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, The serum concentration of Tolvaptan can be increased when it is combined with Digitoxin.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Digitoxin.]
[J05AE07, fosamprenavir, The metabolism of Digitoxin can be decreased when combined with Fosamprenavir.]
[C02KX02, ambrisentan, The serum concentration of Digitoxin can be increased when it is combined with Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Digitoxin can be increased when it is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Digitoxin.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Domperidone.]
[N06AA16, dothiepin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Dosulepin.]
[N06AA12, doxepin, The risk or severity of QTc prolongation can be increased when Doxepin is combined with Digitoxin.]
[L01DB01, doxorubicin, The metabolism of Digitoxin can be decreased when combined with Doxorubicin.]
[R06AA09, doxylamine, The risk or severity of QTc prolongation can be increased when Doxylamine is combined with Digitoxin.]
[N01AB08, sevoflurane, The risk or severity of QTc prolongation can be increased when Sevoflurane is combined with Digitoxin.]
[N05AD08, droperidol, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Droperidol.]
[C10AA01, simvastatin, The serum concentration of Digitoxin can be increased when it is combined with Simvastatin.]
[N05AL02, sultopride, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Sultopride.]
[V04CX07, edrophonium, Edrophonium may increase the atrioventricular blocking (AV block) and arrhythmogenic activities of Digitoxin.]
[C07AB13, talinolol, Digitoxin may increase the arrhythmogenic activities of Talinolol.]
[H01AA01, corticotropin, The risk or severity of adverse effects can be increased when Corticotropin is combined with Digitoxin.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Digitoxin can be increased when combined with Terbinafine.]
[G04BD05, terodiline, Digitoxin may increase the arrhythmogenic activities of Terodiline.]
[C07AA16, tertatolol, Digitoxin may increase the arrhythmogenic activities of Tertatolol.]
[N06BA09, atomoxetine, The risk or severity of QTc prolongation can be increased when Atomoxetine is combined with Digitoxin.]
[N03AX11, topiramate, The metabolism of Digitoxin can be increased when combined with Topiramate.]
[L02BA02, toremifene, The serum concentration of Digitoxin can be increased when it is combined with Toremifene.]
[C03CA04, torsemide, The risk or severity of adverse effects can be increased when Torasemide is combined with Digitoxin.]
[H02CA01, trilostane, The risk or severity of adverse effects can be increased when Trilostane is combined with Digitoxin.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Triptorelin.]
[J01MA04, enoxacin, The risk or severity of QTc prolongation can be increased when Enoxacin is combined with Digitoxin.]
[L01CA04, vinorelbine, Digitoxin may decrease the cardiotoxic activities of Vinorelbine.]
[S01FB02, ephedrine, The risk or severity of Cardiac Arrhythmia can be increased when Ephedrine is combined with Digitoxin.]
[S01GX10, epinastine, The risk or severity of QTc prolongation can be increased when Epinastine is combined with Digitoxin.]
[S01GA03, xylometazoline, Digitoxin may increase the arrhythmogenic activities of Xylometazoline.]
[C08CA12, mepirodipine, Digitoxin may increase the arrhythmogenic activities of Barnidipine.]
[S01EA01, epinephrine, The metabolism of Digitoxin can be decreased when combined with Epinephrine.]
[L01DB03, epirubicin, Digitoxin may decrease the cardiotoxic activities of Epirubicin.]
[N03AX15, zonisamide, Zonisamide may increase the arrhythmogenic activities of Digitoxin.]
[C01BG01, moricizine, Moricizine may increase the arrhythmogenic activities of Digitoxin.]
[A11CC01, ergocalciferol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Ergocalciferol is combined with Digitoxin.]
[N02CA02, ergotamine, The metabolism of Digitoxin can be decreased when combined with Ergotamine.]
[S01AA17, erythromycin, The serum concentration of Digitoxin can be increased when it is combined with Erythromycin.]
[J04AK02, ethambutol, The metabolism of Digitoxin can be decreased when combined with Ethambutol.]
[R03BA09, fluticasone furoate, The risk or severity of adverse effects can be increased when Fluticasone furoate is combined with Digitoxin.]
[R03BA05, fluticasone, The risk or severity of adverse effects can be increased when Fluticasone is combined with Digitoxin.]
[D07AC21, halobetasol, The risk or severity of adverse effects can be increased when Ulobetasol is combined with Digitoxin.]
[C01BD05, ibutilide, Ibutilide may increase the arrhythmogenic activities of Digitoxin.]
[N03AD01, ethosuximide, Ethosuximide may increase the arrhythmogenic activities of Digitoxin.]
[L01CB01, etoposide, The serum concentration of Digitoxin can be increased when it is combined with Etoposide.]
[C01BA05, ajmaline, Digitoxin may increase the arrhythmogenic activities of Ajmaline.]
[L04AD02, tacrolimus, The serum concentration of Digitoxin can be increased when it is combined with Tacrolimus.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Fleroxacin.]
[R06AX11, astemizole, The metabolism of Digitoxin can be decreased when combined with Astemizole.]
[R06AX12, terfenadine, The metabolism of Digitoxin can be decreased when combined with Terfenadine.]
[N06AB08, fluvoxamine, The metabolism of Digitoxin can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, Tocainide may increase the arrhythmogenic activities of Digitoxin.]
[C01BC08, encainide, Encainide may increase the arrhythmogenic activities of Digitoxin.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Leuprolide.]
[C10AA03, pravastatin, The serum concentration of Digitoxin can be increased when it is combined with Pravastatin.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Digitoxin.]
[P02CA03, albendazole, The metabolism of Digitoxin can be decreased when combined with Albendazole.]
[C08CA02, felodipine, Felodipine may increase the arrhythmogenic activities of Digitoxin.]
[C08EA01, fendiline, Digitoxin may increase the arrhythmogenic activities of Fendiline.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Digitoxin.]
[L04AA40, cladribine, Digitoxin may decrease the cardiotoxic activities of Cladribine.]
[C01BC04, flecainide, Flecainide may increase the arrhythmogenic activities of Digitoxin.]
[J01CF05, floxacillin, The metabolism of Digitoxin can be increased when combined with Flucloxacillin.]
[J02AC01, fluconazole, The serum concentration of Digitoxin can be increased when it is combined with Fluconazole.]
[H02AA02, fludrocortisone, The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Digitoxin.]
[D07XB01, flumethasone, The risk or severity of adverse effects can be increased when Flumethasone is combined with Digitoxin.]
[N07CA03, flunarizine, Digitoxin may increase the arrhythmogenic activities of Flunarizine.]
[D07AC08, fluocinonide, The risk or severity of adverse effects can be increased when Fluocinonide is combined with Digitoxin.]
[H02AB03, fluocortolone, The risk or severity of adverse effects can be increased when Fluocortolone is combined with Digitoxin.]
[V03AZ01, ethanol, The metabolism of Digitoxin can be increased when combined with Ethanol.]
[S01CB05, fluorometholone, The risk or severity of adverse effects can be increased when Fluorometholone is combined with Digitoxin.]
[L01BC02, fluorouracil, Digitoxin may decrease the cardiotoxic activities of Fluorouracil.]
[N06AB03, fluoxetine, The risk or severity of QTc prolongation can be increased when Fluoxetine is combined with Digitoxin.]
[N05AF01, flupenthixol, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Flupentixol.]
[D07AC07, flurandrenolide, The risk or severity of adverse effects can be increased when Flurandrenolide is combined with Digitoxin.]
[N05AG01, fluspirilene, Digitoxin may increase the arrhythmogenic activities of Fluspirilene.]
[M03AA01, alcuronium, The risk or severity of Cardiac Arrhythmia can be increased when Alcuronium is combined with Digitoxin.]
[J05AE10, darunavir, The serum concentration of Digitoxin can be increased when it is combined with Darunavir.]
[C03CA01, furosemide, The risk or severity of adverse effects can be increased when Furosemide is combined with Digitoxin.]
[N05AL05, amisulpride, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Digitoxin.]
[M03AC02, gallamine, The risk or severity of Cardiac Arrhythmia can be increased when Gallamine is combined with Digitoxin.]
[C08DA02, gallopamil, Digitoxin may increase the arrhythmogenic activities of Gallopamil.]
[N03AA04, barbexaclone, The metabolism of Digitoxin can be increased when combined with Barbexaclone.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Degarelix.]
[L01EA02, dasatinib, The metabolism of Digitoxin can be decreased when combined with Dasatinib.]
[N04BC06, cabergoline, The serum concentration of Cabergoline can be increased when it is combined with Digitoxin.]
[J05AG04, etravirine, The metabolism of Digitoxin can be increased when combined with Etravirine.]
[A12AA13, calcium citrate, Calcium citrate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
[A12AA10, calcium gluceptate, Calcium glucoheptonate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
[A12AA05, calcium lactate, Calcium lactate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
[A12AA30, calcium levulinate, Calcium levulinate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
[N03AD03, methsuximide, Digitoxin may increase the arrhythmogenic activities of Methsuximide.]
[L01EH01, lapatinib, The serum concentration of Digitoxin can be increased when it is combined with Lapatinib.]
[A10BB01, glyburide, The metabolism of Digitoxin can be decreased when combined with Glyburide.]
[B05CX03, glycine, The risk or severity of adverse effects can be increased when Glycine is combined with Digitoxin.]
[C01BD04, dofetilide, Dofetilide may increase the arrhythmogenic activities of Digitoxin.]
[C02CA04, doxazosin, The metabolism of Digitoxin can be decreased when combined with Doxazosin.]
[L01EX02, sorafenib, The serum concentration of Digitoxin can be increased when it is combined with Sorafenib.]
[C07AB09, esmolol, Esmolol may increase the arrhythmogenic activities of Digitoxin.]
[D01BA01, griseofulvin, The metabolism of Digitoxin can be increased when combined with Griseofulvin.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Halofantrine.]
[D07AD02, halcinonide, The risk or severity of adverse effects can be increased when Halcinonide is combined with Digitoxin.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Haloperidol.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Histrelin.]
[N05AH04, quetiapine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Quetiapine.]
[C09CA01, losartan, Losartan may increase the arrhythmogenic activities of Digitoxin.]
[G03DC01, allylestrenol, The metabolism of Digitoxin can be decreased when combined with Allylestrenol.]
[A07EC02, mesalamine, The serum concentration of Digitoxin can be decreased when it is combined with Mesalazine.]
[C08CA10, nilvadipine, Digitoxin may increase the arrhythmogenic activities of Nilvadipine.]
[M02AA26, nimesulide, Digitoxin may increase the arrhythmogenic activities of Nimesulide.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Oxatomide.]
[C02DB02, hydralazine, The metabolism of Digitoxin can be decreased when combined with Hydralazine.]
[C03AA03, hydrochlorothiazide, Hydrochlorothiazide may increase the hypokalemic activities of Digitoxin.]
[S02BA01, hydrocortisone, The risk or severity of adverse effects can be increased when Hydrocortisone is combined with Digitoxin.]
[D07AC16, hydrocortisone aceponate, The risk or severity of adverse effects can be increased when Hydrocortisone aceponate is combined with Digitoxin.]
[C03AA02, hydroflumethiazide, Hydroflumethiazide may increase the hypokalemic activities of Digitoxin.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Hydroxychloroquine.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Hydroxyzine.]
[J04AB04, rifabutin, The metabolism of Digitoxin can be increased when combined with Rifabutin.]
[S01BA13, rimexolone, The risk or severity of adverse effects can be increased when Rimexolone is combined with Digitoxin.]
[L01DB06, idarubicin, Digitoxin may decrease the cardiotoxic activities of Idarubicin.]
[L01AA06, ifosfamide, The metabolism of Digitoxin can be increased when combined with Ifosfamide.]
[N06AA02, imipramine, The serum concentration of Imipramine can be increased when it is combined with Digitoxin.]
[L01CD01, paclitaxel, The metabolism of Digitoxin can be increased when combined with Paclitaxel.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Terlipressin.]
[R01AD07, tixocortol, The risk or severity of adverse effects can be increased when Tixocortol is combined with Digitoxin.]
[M03BX02, tizanidine, The risk or severity of QTc prolongation can be increased when Tizanidine is combined with Digitoxin.]
[L01CE01, topotecan, The serum concentration of Topotecan can be increased when it is combined with Digitoxin.]
[C03BA11, indapamide, The risk or severity of adverse effects can be increased when Indapamide is combined with Digitoxin.]
[N06AX17, milnacipran, The metabolism of Digitoxin can be decreased when combined with Milnacipran.]
[A10BH01, sitagliptin, The serum concentration of Digitoxin can be increased when it is combined with Sitagliptin.]
[R06AE01, buclizine, The risk or severity of QTc prolongation can be increased when Buclizine is combined with Digitoxin.]
[C10AA06, cerivastatin, The metabolism of Digitoxin can be increased when combined with Cerivastatin.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Anagrelide.]
[C07AA01, alprenolol, Alprenolol may increase the arrhythmogenic activities of Digitoxin.]
[C03BA02, quinethazone, The risk or severity of adverse effects can be increased when Quinethazone is combined with Digitoxin.]
[N01AB06, isoflurane, The risk or severity of QTc prolongation can be increased when Isoflurane is combined with Digitoxin.]
[J04AC01, isoniazid, The metabolism of Digitoxin can be decreased when combined with Isoniazid.]
[J01FA07, josamycin, The serum concentration of Digitoxin can be increased when it is combined with Josamycin.]
[S01AA24, kanamycin, The risk or severity of adverse effects can be increased when Kanamycin is combined with Digitoxin.]
[A07BC02, kaolin, The serum concentration of Digitoxin can be decreased when it is combined with Kaolin.]
[L04AC07, tocilizumab, The metabolism of Digitoxin can be increased when combined with Tocilizumab.]
[J02AB02, ketoconazole, The metabolism of Digitoxin can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The risk or severity of QTc prolongation can be increased when Olanzapine is combined with Digitoxin.]
[V03AC03, deferasirox, The metabolism of Digitoxin can be increased when combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Digitoxin can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Mizolastine.]
[J01MB02, nalidixic acid, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Nalidixic acid.]
[C07AG01, labetalol, Labetalol may increase the bradycardic activities of Digitoxin.]
[N04BB01, amantadine, The risk or severity of QTc prolongation can be increased when Amantadine is combined with Digitoxin.]
[N03AX18, lacosamide, The metabolism of Digitoxin can be decreased when combined with Lacosamide.]
[C03CC01, ethacrynic acid, The risk or severity of adverse effects can be increased when Etacrynic acid is combined with Digitoxin.]
[L01DC03, mitomycin, Digitoxin may decrease the cardiotoxic activities of Mitomycin.]
[S02DA01, lidocaine, Lidocaine may increase the arrhythmogenic activities of Digitoxin.]
[C08EX01, lidoflazine, Digitoxin may increase the arrhythmogenic activities of Lidoflazine.]
[S01AA21, amikacin, The risk or severity of adverse effects can be increased when Amikacin is combined with Digitoxin.]
[N06BA13, armodafinil, The metabolism of Digitoxin can be increased when combined with Armodafinil.]
[C03DB01, amiloride, Amiloride may decrease the excretion rate of Digitoxin which could result in a higher serum level.]
[A07DA03, loperamide, Loperamide may increase the arrhythmogenic activities of Digitoxin.]
[C10AA02, lovastatin, The metabolism of Digitoxin can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The serum concentration of Digitoxin can be increased when it is combined with Loxapine.]
[L01EG01, temsirolimus, The serum concentration of Digitoxin can be increased when it is combined with Temsirolimus.]
[V04CC02, magnesium sulfate, Magnesium sulfate may increase the arrhythmogenic activities of Digitoxin.]
[L01EA03, nilotinib, The metabolism of Digitoxin can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, The serum concentration of Digitoxin can be increased when it is combined with Mannitol.]
[N06AA21, maprotiline, The risk or severity of QTc prolongation can be increased when Maprotiline is combined with Digitoxin.]
[L01AA05, mechlorethamine, Digitoxin may decrease the cardiotoxic activities of Mechlorethamine.]
[C01AA08, medigoxin, Digitoxin may increase the arrhythmogenic activities of Metildigoxin.]
[P01BC02, mefloquine, The serum concentration of Digitoxin can be increased when it is combined with Mefloquine.]
[N02AB02, meperidine, The metabolism of Digitoxin can be decreased when combined with Meperidine.]
[N03AA01, mephobarbital, The metabolism of Digitoxin can be increased when combined with Methylphenobarbital.]
[L02BG01, aminoglutethimide, The metabolism of Digitoxin can be increased when combined with Aminoglutethimide.]
[N05AC03, mesoridazine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Mesoridazine.]
[N05AX13, paliperidone, The serum concentration of Digitoxin can be increased when it is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Dolasetron.]
[H01CB03, lanreotide, The metabolism of Digitoxin can be decreased when combined with Lanreotide.]
[N07BC02, methadone, The metabolism of Digitoxin can be decreased when combined with Methadone.]
[H03BB02, methimazole, The serum concentration of Digitoxin can be increased when it is combined with Methimazole.]
[N02BG08, ziconotide, Digitoxin may increase the arrhythmogenic activities of Ziconotide.]
[L04AX03, methotrexate, Digitoxin may decrease the cardiotoxic activities of Methotrexate.]
[N05AA02, methotrimeprazine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Methotrimeprazine.]
[C03AA08, methyclothiazide, Methyclothiazide may increase the hypokalemic activities of Digitoxin.]
[V04CG05, methylene blue, The serum concentration of Digitoxin can be increased when it is combined with Methylene blue.]
[G02AB01, methylergonovine, The metabolism of Digitoxin can be decreased when combined with Methylergometrine.]
[H02AB04, methylprednisolone, The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Digitoxin.]
[D07AC14, methylprednisolone aceponate, The risk or severity of adverse effects can be increased when Methylprednisolone aceponate is combined with Digitoxin.]
[N03AF03, rufinamide, The metabolism of Digitoxin can be increased when combined with Rufinamide.]
[N02CA04, methysergide, The metabolism of Digitoxin can be decreased when combined with Methysergide.]
[A03FA01, metoclopramide, The risk or severity of QTc prolongation can be increased when Metoclopramide is combined with Digitoxin.]
[C03BA08, metolazone, The risk or severity of adverse effects can be increased when Metolazone is combined with Digitoxin.]
[C07AB02, metoprolol, Metoprolol may increase the arrhythmogenic activities of Digitoxin.]
[P01AB01, metronidazole, The metabolism of Digitoxin can be decreased when combined with Metronidazole.]
[V04CD01, metyrapone, The metabolism of Digitoxin can be increased when combined with Metyrapone.]
[C01BB02, mexiletine, Mexiletine may increase the arrhythmogenic activities of Digitoxin.]
[S02AA13, miconazole, The metabolism of Digitoxin can be decreased when combined with Miconazole.]
[N05CD08, midazolam, The metabolism of Digitoxin can be decreased when combined with Midazolam.]
[C01CA17, midodrine, Digitoxin may increase the bradycardic, atrioventricular blocking (AV block), and arrhythmogenic activities of Midodrine.]
[G03XB01, mifepristone, The serum concentration of Digitoxin can be decreased when it is combined with Mifepristone.]
[J01FA11, miocamycin, The metabolism of Digitoxin can be decreased when combined with Miocamycin.]
[L01XX23, mitotane, The metabolism of Digitoxin can be increased when combined with Mitotane.]
[L01DB07, mitoxantrone, Digitoxin may decrease the cardiotoxic activities of Mitoxantrone.]
[L03AC01, aldesleukin, The metabolism of Digitoxin can be decreased when combined with Aldesleukin.]
[C01BD01, amiodarone, The serum concentration of Digitoxin can be increased when it is combined with Amiodarone.]
[N06AA09, amitriptyline, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Amitriptyline.]
[N02AA01, morphine, The serum concentration of Digitoxin can be increased when it is combined with Morphine.]
[L04AB05, certolizumab pegol, The metabolism of Digitoxin can be increased when combined with Certolizumab pegol.]
[L01EX03, pazopanib, The metabolism of Digitoxin can be decreased when combined with Pazopanib.]
[M03AC03, vecuronium, The risk or severity of Cardiac Arrhythmia can be increased when Vecuronium is combined with Digitoxin.]
[N05CA02, amobarbital, The metabolism of Digitoxin can be increased when combined with Amobarbital.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Digitoxin.]
[G04CA04, silodosin, The serum concentration of Digitoxin can be increased when it is combined with Silodosin.]
[G03XC01, raloxifene, The metabolism of Digitoxin can be decreased when combined with Raloxifene.]
[N06AA17, amoxapine, The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Digitoxin.]
[N03AB05, fosphenytoin, The metabolism of Digitoxin can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, Nadolol may increase the arrhythmogenic activities of Digitoxin.]
[J01CF06, nafcillin, The metabolism of Digitoxin can be increased when combined with Nafcillin.]
[V03AB15, naloxone, The metabolism of Digitoxin can be decreased when combined with Naloxone.]
[L04AC03, anakinra, The metabolism of Digitoxin can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The risk or severity of Cardiac Arrhythmia can be increased when Naphazoline is combined with Digitoxin.]
[A10BG01, troglitazone, The metabolism of Digitoxin can be increased when combined with Troglitazone.]
[L01CD02, docetaxel, The metabolism of Digitoxin can be decreased when combined with Docetaxel.]
[S03AA01, neomycin, The risk or severity of adverse effects can be increased when Neomycin is combined with Digitoxin.]
[C01CX08, levosimendan, Levosimendan may increase the arrhythmogenic activities of Digitoxin.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Digitoxin.]
[S01AA23, netilmicin, The risk or severity of adverse effects can be increased when Netilmicin is combined with Digitoxin.]
[N06AX23, desvenlafaxine, The metabolism of Digitoxin can be decreased when combined with Desvenlafaxine.]
[C09CA07, telmisartan, The serum concentration of Digitoxin can be increased when it is combined with Telmisartan.]
[H05BX02, paricalcitol, The risk or severity of ventricular arrhythmias and Cardiac Arrhythmia can be increased when Paricalcitol is combined with Digitoxin.]
[L01XX01, amsacrine, Digitoxin may decrease the cardiotoxic activities of Amsacrine.]
[C10AD02, niacin, The metabolism of Digitoxin can be decreased when combined with Niacin.]
[C08CA04, nicardipine, Nicardipine may increase the arrhythmogenic activities of Digitoxin.]
[C08CA05, nifedipine, Nifedipine may increase the arrhythmogenic activities of Digitoxin.]
[C08CA06, nimodipine, Nimodipine may increase the arrhythmogenic activities of Digitoxin.]
[C08CA07, nisoldipine, Nisoldipine may increase the arrhythmogenic activities of Digitoxin.]
[C08CA08, nitrendipine, Nitrendipine may increase the arrhythmogenic activities of Digitoxin.]
[C01CA03, norepinephrine, The risk or severity of Cardiac Arrhythmia can be increased when Norepinephrine is combined with Digitoxin.]
[G03DC02, norethindrone, The metabolism of Digitoxin can be decreased when combined with Norethisterone.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Digitoxin.]
[C02KX01, bosentan, The metabolism of Digitoxin can be increased when combined with Bosentan.]
[N06AA10, nortriptyline, The risk or severity of QTc prolongation can be increased when Nortriptyline is combined with Digitoxin.]
[R05DA07, noscapine, The metabolism of Digitoxin can be decreased when combined with Noscapine.]
[A16AX07, sapropterin, The serum concentration of Digitoxin can be increased when it is combined with Sapropterin.]
[G02CA02, nylidrin, Digitoxin may increase the arrhythmogenic activities of Nylidrin.]
[H01CB02, octreotide, The serum concentration of Digitoxin can be increased when it is combined with Octreotide.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Ofloxacin.]
[J01FA05, oleandomycin, The metabolism of Digitoxin can be decreased when combined with Oleandomycin.]
[L04AC04, rilonacept, The metabolism of Digitoxin can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Digitoxin can be increased when combined with Omeprazole.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Oxolinic acid.]
[C07AA02, oxprenolol, Digitoxin may increase the arrhythmogenic activities of Oxprenolol.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Digitoxin can be decreased when used in combination with Oxymetazoline.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Digitoxin.]
[J04AA01, aminosalicylic acid, The serum concentration of Digitoxin can be decreased when it is combined with Aminosalicylic acid.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Asenapine.]
[M03AC01, pancuronium, The risk or severity of Cardiac Arrhythmia can be increased when Pancuronium is combined with Digitoxin.]
[J04AB30, capreomycin, The risk or severity of adverse effects can be increased when Capreomycin is combined with Digitoxin.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Papaverine.]
[H02AB05, paramethasone, The risk or severity of adverse effects can be increased when Paramethasone is combined with Digitoxin.]
[A07AA06, paromomycin, The risk or severity of adverse effects can be increased when Paromomycin is combined with Digitoxin.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Digitoxin.]
[C07AA23, penbutolol, Penbutolol may increase the bradycardic activities of Digitoxin.]
[N05AG03, penfluridol, Digitoxin may increase the arrhythmogenic activities of Penfluridol.]
[N05CA01, pentobarbital, The metabolism of Digitoxin can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Digitoxin may decrease the cardiotoxic activities of Pentostatin.]
[C08EX02, perhexiline, Perhexiline may increase the arrhythmogenic activities of Digitoxin.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Pheniramine.]
[N03AA02, phenobarbital, The metabolism of Digitoxin can be increased when combined with Phenobarbital.]
[M02AA01, phenylbutazone, The metabolism of Digitoxin can be increased when combined with Phenylbutazone.]
[N03AB02, phenytoin, The metabolism of Digitoxin can be increased when combined with Phenytoin.]
[L04AB06, golimumab, The metabolism of Digitoxin can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Levofloxacin.]
[L02BB03, bicalutamide, The metabolism of Digitoxin can be decreased when combined with Bicalutamide.]
[C08CX01, mibefradil, Mibefradil may increase the arrhythmogenic activities of Digitoxin.]
[N05AG02, pimozide, The metabolism of Digitoxin can be decreased when combined with Pimozide.]
[C07AA03, pindolol, Pindolol may increase the bradycardic activities of Digitoxin.]
[J05AE01, saquinavir, The metabolism of Digitoxin can be decreased when combined with Saquinavir.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Grepafloxacin.]
[J05AG02, delavirdine, The metabolism of Digitoxin can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, The metabolism of Digitoxin can be decreased when combined with Irbesartan.]
[L02BG03, anastrozole, Digitoxin may decrease the cardiotoxic activities of Anastrozole.]
[L04AC08, canakinumab, The metabolism of Digitoxin can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, Polythiazide may increase the hypokalemic activities of Digitoxin.]
[J05AE03, ritonavir, The serum concentration of Digitoxin can be increased when it is combined with Ritonavir.]
[V03AB21, potassium iodide, The serum concentration of Digitoxin can be increased when it is combined with Potassium Iodide.]
[C07AB01, practolol, Practolol may increase the arrhythmogenic activities of Digitoxin.]
[C01BA08, prajmaline, Digitoxin may increase the arrhythmogenic activities of Prajmaline.]
[S03BA02, prednisolone, The risk or severity of adverse effects can be increased when Prednisolone is combined with Digitoxin.]
[H02AB07, prednisone, The risk or severity of adverse effects can be increased when Prednisone is combined with Digitoxin.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Antazoline.]
[C01DX02, prenylamine, Digitoxin may increase the arrhythmogenic activities of Prenylamine.]
[P01BA03, primaquine, The metabolism of Digitoxin can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Digitoxin can be increased when combined with Primidone.]
[M04AB01, probenecid, The metabolism of Digitoxin can be increased when combined with Probenecid.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Probucol.]
[C01BA02, procainamide, Procainamide may increase the arrhythmogenic activities of Digitoxin.]
[C10AB05, fenofibrate, The metabolism of Digitoxin can be decreased when combined with Fenofibrate.]
[N05AB04, prochlorperazine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Prochlorperazine.]
[N05AA03, promazine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Promazine.]
[R06AD02, promethazine, The risk or severity of QTc prolongation can be increased when Promethazine is combined with Digitoxin.]
[C01BC03, propafenone, The serum concentration of Digitoxin can be increased when it is combined with Propafenone.]
[R06AX26, fexofenadine, The serum concentration of Digitoxin can be increased when it is combined with Fexofenadine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Romidepsin.]
[N01AX10, propofol, The metabolism of Digitoxin can be decreased when combined with Propofol.]
[N02AC04, propoxyphene, The metabolism of Digitoxin can be decreased when combined with Dextropropoxyphene.]
[C07AA05, propranolol, Propranolol may increase the arrhythmogenic activities of Digitoxin.]
[H03BA02, propylthiouracil, The serum concentration of Digitoxin can be increased when it is combined with Propylthiouracil.]
[N06AA11, protriptyline, The risk or severity of QTc prolongation can be increased when Protriptyline is combined with Digitoxin.]
[N05AX12, aripiprazole, The risk or severity of QTc prolongation can be increased when Aripiprazole is combined with Digitoxin.]
[P02CC01, pyrantel, The risk or severity of Cardiac Arrhythmia can be increased when Pyrantel is combined with Digitoxin.]
[R06AC01, pyrilamine, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Mepyramine.]
[C01BA01, quinidine, The serum concentration of Digitoxin can be increased when it is combined with Quinidine.]
[P01BC01, quinine, The serum concentration of Digitoxin can be increased when it is combined with Quinine.]
[D07AC10, diflorasone, The risk or severity of adverse effects can be increased when Diflorasone is combined with Digitoxin.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Digitoxin.]
[J04AB02, rifampin, The serum concentration of Digitoxin can be decreased when it is combined with Rifampicin.]
[J01FA06, roxithromycin, The metabolism of Digitoxin can be decreased when combined with Roxithromycin.]
[A07EC01, sulfasalazine, The serum concentration of Digitoxin can be decreased when it is combined with Sulfasalazine.]
[S01BC08, salicylic acid, The serum concentration of Digitoxin can be decreased when it is combined with Salicylic acid.]
[N05CA06, secobarbital, The metabolism of Digitoxin can be increased when combined with Secobarbital.]
[J01GB08, sisomicin, The risk or severity of adverse effects can be increased when Sisomicin is combined with Digitoxin.]
[H01CB01, somatostatin, The metabolism of Digitoxin can be decreased when combined with Somatostatin.]
[C07AA07, sotalol, Sotalol may increase the arrhythmogenic activities of Digitoxin.]
[L01CD04, cabazitaxel, The serum concentration of Cabazitaxel can be increased when it is combined with Digitoxin.]
[C03DA01, spironolactone, Spironolactone may decrease the excretion rate of Digitoxin which could result in a higher serum level.]
[N03AG01, valproic acid, The metabolism of Digitoxin can be decreased when combined with Valproic acid.]
[D07AB02, hydrocortisone butyrate, The risk or severity of adverse effects can be increased when Hydrocortisone butyrate is combined with Digitoxin.]
[D07AB11, hydrocortisone probutate, The risk or severity of adverse effects can be increased when Hydrocortisone probutate is combined with Digitoxin.]
[L01CD03, paclitaxel poliglumex, Digitoxin may decrease the cardiotoxic activities of Paclitaxel poliglumex.]
[H02CA04, levoketoconazole, The metabolism of Digitoxin can be decreased when combined with Levoketoconazole.]
[A12AA11, calcium pangamate, Calcium pangamate may increase the arrhythmogenic and cardiotoxic activities of Digitoxin.]
